Literature DB >> 28097735

Autoimmune enteropathy and hepatitis in pediatric heart transplant recipient.

Kimberly Lewis1, Ryan Butts2, J Antonio Quiros3, Michelle Hudspeth4, Katherine Twombley5, Andrew Savage2, Sally Self6, Ali Burnette2, Shaoli Sun6.   

Abstract

AIE is a rare disorder in children that presents with severe diarrhea and malabsorption, caused by immune-mediated damage to intestinal mucosa. AIE is often associated with various syndromes of immunodeficiency including IPEX syndrome (immune dysregulation, polyendocrinopathy and enteropathy, X-linked). Dysfunctional T regulatory cells are the source of pathology in both IPEX syndrome and AIE as they are essential in maintaining tolerance to self-antigens and eliminating autoreactive B cells. This case report describes a 10-year-old cardiac transplant and total thymectomy patient on chronic immunosuppression with tacrolimus that presented with AIE and extraintestinal manifestations of cyclical hepatitis. Transition from tacrolimus to sirolimus successfully increased T regulatory cells and resolved enteritis and hepatitis symptoms. Data support that thymectomy at <1 year of age increases risk of autoimmune disease due to abnormal immune maturation. Studies suggest that the sirolimus promotes the upregulation of the FoxP3 protein that is classically associated with Tregs. In turn, Tregs prevent the maturation of autoreactive B cells that lead to autoimmune reactions.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  T lymphocytes; autoimmune enteropathy; heart transplant; sirolimus; solid organ transplantation; thymectomy

Mesh:

Substances:

Year:  2017        PMID: 28097735     DOI: 10.1111/petr.12877

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  1 in total

1.  Case Report: "Primary Immunodeficiency"-Severe Autoimmune Enteropathy in a Pediatric Heart Transplant Recipient Treated With Abatacept and Alemtuzumab.

Authors:  Elizaveta Kalaidina; Elizabeth C Utterson; Deepa Mokshagundam; Mai He; Shalini Shenoy; Megan A Cooper
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.